Histone deacetylase inhibitors (HDACi) are endowed with plethora of biological functions including anti-proliferative, anti-inflammatory, anti-parasitic, and cognition-enhancing activities. Parsing the structure-activity relationship (SAR) for each disease condition is vital for long-term therapeutic applications of HDACi. We report in the present study specific cap group substitution patterns and spacer-group chain lengths that enhance the antimalarial and antileishmanial activity of aryltriazolylhydroxamates-based HDACi. We identified many compounds that are several folds selectively cytotoxic to the plasmodium parasites compared to standard HDACi. Also, a few of these compounds have antileishmanial activity that rivals that of miltefosine, the only currently available oral agent against visceral leishmaniasis. The anti-parasite properties of several of these compounds tracked well with their anti-HDAC activities. The results presented here provide further evidence on the suitability of HDAC inhibition as a viable therapeutic option to curb infections caused by apicomplexan protozoans and trypanosomatids. Copyright (c) 2009 Elsevier Ltd. All rights reserved.
Histone deacetylase inhibitors (HDACi) are endowed with plethora of biological functions including anti-proliferative, anti-inflammatory, anti-parasitic, and cognition-enhancing activities. Parsing the structure-activity relationship (SAR) for each disease condition is vital for long-term therapn>eutic apn>plications of n>an class="Gene">HDACi. We report in the present study specific cap group substitution patterns and spacer-group chain lengths that enhance the antimalarial and antileishmanial activity of aryltriazolylhydroxamates-based HDACi. We identified many compounds that are several folds selectively cytotoxic to the plasmodium parasites compared to standard HDACi. Also, a few of these compounds have antileishmanial activity that rivals that of miltefosine, the only currently available oral agent against visceral leishmaniasis. The anti-parasite properties of several of these compounds tracked well with their anti-HDAC activities. The results presented here provide further evidence on the suitability of HDAC inhibition as a viable therapeutic option to curb infections caused by apicomplexan protozoans and trypanosomatids. Copyright (c) 2009 Elsevier Ltd. All rights reserved.
Authors: Alasdair C Ivens; Christopher S Peacock; Elizabeth A Worthey; Lee Murphy; Gautam Aggarwal; Matthew Berriman; Ellen Sisk; Marie-Adele Rajandream; Ellen Adlem; Rita Aert; Atashi Anupama; Zina Apostolou; Philip Attipoe; Nathalie Bason; Christopher Bauser; Alfred Beck; Stephen M Beverley; Gabriella Bianchettin; Katja Borzym; Gordana Bothe; Carlo V Bruschi; Matt Collins; Eithon Cadag; Laura Ciarloni; Christine Clayton; Richard M R Coulson; Ann Cronin; Angela K Cruz; Robert M Davies; Javier De Gaudenzi; Deborah E Dobson; Andreas Duesterhoeft; Gholam Fazelina; Nigel Fosker; Alberto Carlos Frasch; Audrey Fraser; Monika Fuchs; Claudia Gabel; Arlette Goble; André Goffeau; David Harris; Christiane Hertz-Fowler; Helmut Hilbert; David Horn; Yiting Huang; Sven Klages; Andrew Knights; Michael Kube; Natasha Larke; Lyudmila Litvin; Angela Lord; Tin Louie; Marco Marra; David Masuy; Keith Matthews; Shulamit Michaeli; Jeremy C Mottram; Silke Müller-Auer; Heather Munden; Siri Nelson; Halina Norbertczak; Karen Oliver; Susan O'neil; Martin Pentony; Thomas M Pohl; Claire Price; Bénédicte Purnelle; Michael A Quail; Ester Rabbinowitsch; Richard Reinhardt; Michael Rieger; Joel Rinta; Johan Robben; Laura Robertson; Jeronimo C Ruiz; Simon Rutter; David Saunders; Melanie Schäfer; Jacquie Schein; David C Schwartz; Kathy Seeger; Amber Seyler; Sarah Sharp; Heesun Shin; Dhileep Sivam; Rob Squares; Steve Squares; Valentina Tosato; Christy Vogt; Guido Volckaert; Rolf Wambutt; Tim Warren; Holger Wedler; John Woodward; Shiguo Zhou; Wolfgang Zimmermann; Deborah F Smith; Jenefer M Blackwell; Kenneth D Stuart; Bart Barrell; Peter J Myler Journal: Science Date: 2005-07-15 Impact factor: 47.728
Authors: Dante Rotili; Giovanna Simonetti; Andrea Savarino; Anna T Palamara; Anna R Migliaccio; Antonello Mai Journal: Curr Top Med Chem Date: 2009 Impact factor: 3.295
Authors: Vishal Patel; Ralph Mazitschek; Bradley Coleman; Cokey Nguyen; Sameer Urgaonkar; Joseph Cortese; Robert H Barker; Edward Greenberg; Weiping Tang; James E Bradner; Stuart L Schreiber; Manoj T Duraisingh; Dyann F Wirth; Jon Clardy Journal: J Med Chem Date: 2009-04-23 Impact factor: 7.446
Authors: William Guerrant; Sandra C Mwakwari; Po C Chen; Shabana I Khan; Babu L Tekwani; Adegboyega K Oyelere Journal: ChemMedChem Date: 2010-08-02 Impact factor: 3.466
Authors: Sandra C Mwakwari; William Guerrant; Vishal Patil; Shabana I Khan; Babu L Tekwani; Zachary A Gurard-Levin; Milan Mrksich; Adegboyega K Oyelere Journal: J Med Chem Date: 2010-08-26 Impact factor: 7.446
Authors: William Guerrant; Vishal Patil; Joshua C Canzoneri; Li-Pan Yao; Rebecca Hood; Adegboyega K Oyelere Journal: Bioorg Med Chem Lett Date: 2013-04-04 Impact factor: 2.823